| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.ase.life | |
| Market Cap | 348.45 Cr. | |
| Enterprise Value(EV) | 368.85 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.38 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 120.78 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 42.15 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 16.72 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 2.72 | Calculated using Price: 45.47 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 7.66 Cr. | 76,633,296 Shares |
| FaceValue | 10 | |
| About Ambalal Sarabhai Enterprises Ltd. | ||
| Ambalal Sarabhai Enterprises is a Baroda-based pharmaceutical manufacturing company which was incorporated in 1977. It is one of the company belonging to the Sarabhai Group. The Group's principal activity is manufacture and marketing of pharmaceutical products and bulk drugs. The company's plants are located at Vadodara and Ahmedabad. | ||
| 1 Day |
|
-1.47% |
| 1 Week |
|
-5.31% |
| 1 Month |
|
-13.03% |
| 3 Month |
|
-22.98% |
| 6 Month |
|
+19.72% |
| 1 Year |
|
+102.45% |
| 2 Year |
|
+28.45% |
| 5 Year |
|
+209.53% |
| 10 Year |
|
+1512.41% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 0 | 328.25 | -57.92 | 4.2 | 7.01 | 40.95 | 49.47 | 48.74 | 8.85 | |
| Return on Capital Employed (%) | 10.08 | 107.14 | -11.94 | 16.34 | 13.17 | 27.14 | 40.28 | 45.53 | 11.08 | |
| Return on Assets (%) | -3.51 | 25.83 | -10.3 | 0.62 | 0.99 | 7.84 | 15.02 | 21.57 | 4.67 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | -9 | 39 | 25 | 27 | 31 | 45 | 74 | 120 | 131 | 127 | |
| Non Curr. Liab. | 15 | 13 | 6 | 11 | 9 | 5 | 5 | 5 | 20 | 13 | |
| Curr. Liab. | 163 | 153 | 124 | 155 | 171 | 133 | 129 | 105 | 95 | 101 | |
| Minority Int. | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Equity & Liab. | 169 | 204 | 155 | 193 | 211 | 183 | 208 | 230 | 246 | 240 | |
| Non Curr. Assets | 100 | 92 | 82 | 80 | 95 | 79 | 87 | 110 | 129 | 130 | |
| Curr. Assets | 68 | 112 | 73 | 114 | 116 | 104 | 121 | 120 | 117 | 110 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 169 | 204 | 155 | 193 | 211 | 183 | 208 | 230 | 246 | 240 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 125 | 132 | 134 | 125 | 152 | 134 | 164 | 197 | 170 | 164 | |
| Other Income | 13 | 95 | 6 | 25 | 5 | 24 | 31 | 42 | 12 | 10 | |
| Total Income | 137 | 227 | 140 | 150 | 157 | 158 | 194 | 239 | 183 | 174 | |
| Total Expenditure | -129 | -145 | -145 | -137 | -146 | -135 | -165 | -172 | -161 | -160 | |
| PBIDT | 9 | 82 | -5 | 13 | 11 | 22 | 29 | 67 | 21 | 14 | |
| Interest | -10 | -4 | -5 | -3 | -3 | -4 | -3 | -2 | -3 | -4 | |
| Depreciation | -5 | -17 | -4 | -2 | -2 | -3 | -2 | -2 | -3 | -4 | |
| Taxation | -1 | -14 | -5 | -7 | -4 | -1 | -3 | -7 | -4 | -3 | |
| Exceptional Items | -15 | ||||||||||
| PAT | -7 | 48 | -19 | 1 | 2 | 15 | 29 | 47 | 11 | 3 | |
| Minority Interest | |||||||||||
| Share Associate | 0 | 0 | 2 | -1 | 0 | ||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | -7 | 48 | -18 | 1 | 4 | 14 | 29 | 47 | 11 | 3 | |
| Adjusted EPS | -1 | 6 | -2 | 0 | 1 | 2 | 4 | 6 | 1 | 0 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 11 | -8 | -75 | 5 | -7 | 19 | -7 | -2 | 11 | 6 | |
| Cash Fr. Inv. | -1 | 10 | 80 | -3 | 18 | -9 | 17 | 10 | 5 | -17 | |
| Cash Fr. Finan. | -8 | -1 | -3 | -6 | -2 | -6 | -14 | -6 | -19 | 9 | |
| Net Change | 2 | 1 | 2 | -4 | 8 | 3 | -4 | 2 | -3 | -2 | |
| Cash & Cash Eqvt | 8 | 8 | 10 | 5 | 14 | 17 | 13 | 15 | 12 | 10 |
|
Wed, 01 May 2024
Announcement under Regulation 30 (LODR)-Change in Management Intimation of Resignation of CFO under Regulation 30 of SEBI (LODR) Regulations 2015. |
|||||||||||||||||||||
|
Wed, 01 May 2024
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) Intimation of Resignation of CFO under Regulation 30 of SEBI (LODR) Regulations 2015. |
|||||||||||||||||||||
|
Thu, 25 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Disha Punjani Designation: Company Secretary and Compliance Officer EmailId: dpunjani@ase.life Name of the Chief Financial Officer: Navinchandra Patel Designation: CFO EmailId: npatel@ase.life Date: 25/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
| Fri, 03 May 2024 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Opening at High
|
Closing Below Previous Low
|
